Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast
Gamida Cell Ltd. (NASDAQ: GMDA) announced a conference call on March 15, 2022, at 8:00 a.m. ET to discuss its Q4 and full year 2021 financial results and provide a company update. The event can be accessed via the Gamida Cell website. The company is known for its diverse immunotherapy pipeline focused on blood cancers, including its investigational product omidubicel, aimed at providing life-saving alternatives for patients needing bone marrow transplants. Gamida Cell emphasizes its commitment to potential cures for serious blood diseases.
- Strong focus on pioneering cell therapies for blood cancers.
- Investigational product omidubicel could provide life-saving options for patients.
- Potential risks associated with clinical trials and regulatory submissions.
- Forward-looking statements are subject to uncertainties, impacting investor confidence.
The webcast will be available on the “Investors & Media” section of the
About
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates (including GDA-201), anticipated regulatory filings (including the timing of submission of the BLA for omidubicel to the FDA), commercialization planning efforts, and the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations for the expected clinical development milestones set forth herein. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005778/en/
For investors:
Stern Investor Relations, Inc.
courtney.turiano@sternir.com
1-212-362-1200
For media:
Ten
rhiannon@tenbridgecommunications.com
1-978-417-1946
Source:
FAQ
When is Gamida Cell's next conference call?
What financial results will Gamida Cell discuss in the conference call?
What is omidubicel?
What is Gamida Cell's focus in cell therapy?